Cargando…

Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis

BACKGROUND: The incidence of DLBCL in elderly patients has been gradually increased. Considering their comorbidities and performance status, the first-line standard treatment hasn’t been determined for the elderly. METHODS: We performed a systemic review and network meta-analysis to compare the effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yangyang, Ren, Xiyang, Huang, Keke, Liang, Xue, Pu, Lianfang, Hu, Linhui, Zhai, Zhimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845876/ https://www.ncbi.nlm.nih.gov/pubmed/36685597 http://dx.doi.org/10.3389/fimmu.2022.1082293

Ejemplares similares

Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma
por: Charwudzi, Alice, et al.
Publicado: (2021)

Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient
por: Hu, Linhui, et al.
Publicado: (2021)

Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients
por: Li, Manman, et al.
Publicado: (2019)

Super-Enhancer–Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients
por: Liang, Xue, et al.
Publicado: (2022)

Integrative analysis of hub genes and key pathway in two subtypes of diffuse large B‐cell lymphoma by bioinformatics and basic experiments
por: Li, Qian, et al.
Publicado: (2021)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
por: Gambella, Massimiliano, et al.
Publicado: (2022)

Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review
por: Tian, Linyan, et al.
Publicado: (2023)

Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
por: Le Gallou, Simon, et al.
Publicado: (2021)

PB2320: FIRST LINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA AMONG THE ELDERLY: A TUNISIAN MULTICENTER EXPERIENCE.
por: Zahra, Kmira, et al.
Publicado: (2023)

Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era
por: Mussetti, Alberto, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome
por: Yin, Zexi, et al.
Publicado: (2021)

Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma
por: Phipps-Yonas, Hannah, et al.
Publicado: (2013)

International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma
por: Mu, Shidai, et al.
Publicado: (2021)

Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma
por: Zhu, Yue, et al.
Publicado: (2022)

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
por: González Barca, Eva
Publicado: (2022)

Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphoma
por: Zhang, Yu, et al.
Publicado: (2023)

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma
por: Li, Haoguang, et al.
Publicado: (2022)

The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma
por: Lin, Zhouning, et al.
Publicado: (2023)

Primary testicular diffuse large B-cell lymphoma: Case series
por: Wang, Qi, et al.
Publicado: (2020)

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
por: Al-Sarayfi, Diana, et al.
Publicado: (2022)

The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study
por: Lu, Chuanyang, et al.
Publicado: (2023)

EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas
por: Turdo, Alice, et al.
Publicado: (2023)

Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients
por: Wang, Zhitao, et al.
Publicado: (2021)

Elevated circulating myeloid‐derived suppressor cells associated with poor prognosis in B‐cell non‐Hodgkin's lymphoma patients
por: Wang, Yangyang, et al.
Publicado: (2022)

Sinonasal diffuse large B-cell lymphoma in a patient with Wiskott–Aldrich syndrome: A case report and literature review
por: Sun, Xiwen, et al.
Publicado: (2023)

Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature
por: Serna, Leyre, et al.
Publicado: (2023)

Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma
por: Wang, Jinghua, et al.
Publicado: (2023)

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
por: Zhang, Xuzhao, et al.
Publicado: (2022)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy
por: Ni, Ying, et al.
Publicado: (2022)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
por: Caballero, Ana Carolina, et al.
Publicado: (2022)

New treatment options in elderly patients with Diffuse Large B-cell Lymphoma
por: Arcari, Annalisa, et al.
Publicado: (2023)

Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy
por: Zhu, Weiguo, et al.
Publicado: (2022)

Degree of stemness predicts micro-environmental response and clinical outcomes of diffuse large B-cell lymphoma and identifies a potential targeted therapy
por: Hu, Fang, et al.
Publicado: (2022)

Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma
por: Li, Yang, et al.
Publicado: (2022)

Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
por: Gupta, Varsha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lvrb2j01vet2v3ij26dp8iqcl7